Global imaging leadership Imaging Endpoints is the largest global imaging CRO in oncology with real-time scan reading across thousands of sites, presenting a wide geographic footprint and scalable capacity for multinational studies.

Strong regulatory track A perfect inspection record and a 95% regulatory approval success rate across over 200 marketing authorizations highlight quality and reliability, offering a compelling case to expand services with risk-averse sponsors.

Deep scientific talent Access to world-class medical and scientific leadership, a large pool of physician readers, and extensive publications position IE as a preferred partner for complex Phase 3 trials and novel imaging biomarkers.

Expansion and partnerships Strategic offices across North America, Europe, and Asia, plus affiliations with major healthcare systems, create opportunities to co-develop studies, leverage referral networks, and win multi-region trial business.

Industry positioning Experience with innovative projects like CD8+/CD4+ PET tracer development signals capability in cutting-edge imaging therapeutics, enabling collaboration with sponsors pursuing advanced diagnostics and companion imaging.